Viracta Therapeutics (NASDAQ:VIRX) Given Outperform Rating at Oppenheimer

Viracta Therapeutics (NASDAQ:VIRX)‘s stock had its “outperform” rating reissued by equities researchers at Oppenheimer in a note issued to investors on Wednesday, Benzinga reports. They presently have a $13.00 target price on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Viracta Therapeutics in a research report on Tuesday.

Viracta Therapeutics Stock Performance

VIRX stock opened at $0.91 on Wednesday. The stock has a market cap of $35.70 million, a P/E ratio of -0.69 and a beta of 0.93. The firm has a 50 day simple moving average of $0.91 and a 200 day simple moving average of $0.70. Viracta Therapeutics has a 52 week low of $0.43 and a 52 week high of $2.38.

Viracta Therapeutics (NASDAQ:VIRX) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.05). Sell-side analysts predict that Viracta Therapeutics will post -1.28 EPS for the current year.

Hedge Funds Weigh In On Viracta Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VIRX. Virtu Financial LLC bought a new position in Viracta Therapeutics during the fourth quarter valued at approximately $29,000. Jane Street Group LLC bought a new position in shares of Viracta Therapeutics in the fourth quarter valued at approximately $35,000. Bank of America Corp DE raised its position in shares of Viracta Therapeutics by 81.3% in the first quarter. Bank of America Corp DE now owns 23,241 shares of the company’s stock valued at $37,000 after purchasing an additional 10,422 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Viracta Therapeutics in the second quarter valued at approximately $52,000. Finally, Two Sigma Investments LP bought a new position in shares of Viracta Therapeutics in the fourth quarter valued at approximately $87,000. Institutional investors own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.